Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) ("60 Degrees" or the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that three ...
Data from the pivotal ENERGY trial showed IMAAVY® produced a rapid and durable hemoglobin responsea in wAIHA Currently no FDA-approved therapies are available for wAIHA ...
Johnson & Johnson (NYSE:JNJ) is one of the 10 best stocks to invest in during a recession. On February 26, 2026, Johnson & ...
Patients with lupus nephritis complicated by thrombotic microangiopathy tend to have high death risk and poor renal outcomes. They need vital and effective therapies.
Precision Bb Targeting, Robust Efficacy, Transfusion Independence, Excellent Safety in Phase II PNH Study, and Subcutaneous Administration The 12-16-week open-label study evaluated Ruxoprubart as ...
The CD19 inhibitors market is projected to expand substantially in the coming years. This growth is driven by a rising number of patients diagnosed with conditions such as NHL, ALL, NMOSD, IgG4-RD, ...
SNY wins Japan orphan drug tag for Waylirz in IgG4-RD and adds regulatory perks as the BTK inhibitor advances in late-stage studies.
Blackstone Life Sciences announced a research and development funding agreement to advance the clinical development of bleximenib, an investigational oral menin inhibitor, for acute myeloid leukemia ...
60 Degrees Pharmaceuticals Inc. (NASDAQ:SXTP) is one of the best up and coming penny stocks to buy. On February 2, 60 Degrees Pharmaceuticals announced a partnership with GoodRx to enhance the ...
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, ...
Sanofi’s rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease Designation based on positive data from a phase 2 study of rilzabrutinib in IgG4-RDThird global orphan drug ...
ZUG, Switzerland and BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the fourth quarter and full year ended December 31, 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results